Publication Date
2019
Journal Title
IDCases
Abstract
© 2019 The Authors Trimethoprim-sulfamethoxazole (TMP-SMX, co-trimoxazole, or bactrim) has been the standard first-line treatment against Pneumocystis jirovecii pneumonia (PCP) for decades. However, adverse effects and cases of treatment failure have led to a search for alternative agents. We present a case of a 50 year old immune compromised female whose course of PCP did not improve until Caspofungin was added to TMP-SMX.
Volume Number
15
Pages
e00496
Document Type
Article
Status
Faculty; Northwell Researcher
Facility
School of Medicine; Northwell Health
Primary Department
Infectious Disease
PMID
DOI
10.1016/j.idcr.2019.e00496